Journal of Diagnostics Concepts & Practice >

2025 , Vol. 24 >Issue 02: 187 - 193

DOI: https://doi.org/10.16150/j.1671-2870.2025.02.010

Distribution of BRAFV600E mutation in cytological samples of thyroid nodules and its clinical application value

  • WANG Lei ,
  • JIN Jingjing ,
  • YU Na ,
  • XIAO Li
Expand
  • Department of Pathology, Huadong Hospital Affiliated to Fudan University, Shanghai 200040, China

Received date: 2024-09-25

  Accepted date: 2025-04-10

  Online published: 2025-07-11

Fold

Abstract

Objective To investigate the distribution characteristics of BRAFV600E mutation in cytological diagnosis of thyroid fine-needle aspiration cytology (FNAC) and analyze the diagnostic value of combining FNAC with BRAFV600E mutation detection for the preoperative diagnosis of papillary thyroid carcinoma (PTC). Methods A retrospective analysis was conducted on 261 consecutive thyroid nodules that underwent FNAC at Huadong Hospital Affiliated to Fudan University between November 2021 and January 2024. All nodules were tested for mutations in BRAF, TERT, RET, HRAS, KRAS, NRAS, PPARG, and NTRK genes using the amplification refractory mutation system-polymerase chain reaction (ARMS-PCR). The distribution of BRAFV600E mutations across the Bethesda system for reporting thyroid cytopathology (TBSRTC) was analyzed. Among the 261 thyroid nodules, 69 underwent postoperative histopathological examination, including 65 diagnosed as PTC, 3 as follicular tumors, and 1 as a follicular nodule. Using postoperative histopathology as the gold standard, the diagnostic value (accuracy, sensitivity, and specificity) of FNAC combined with BRAFV600E mutation detection for preoperative PTC diagnosis was analyzed. Results Among the 261 FNAC samples, 98 thyroid nodules were BRAFV600E -positive, with 78.6% of positive samples classified as category Ⅴ or Ⅵ in the TBSRTC. The accuracy of FNAC, BRAFV600E mutation detection, and their combination in differentiating PTC was 76.8%, 81.2%, and 89.9%, respectively. The sensitivi-ty was 76.9%, 80.0%, and 90.8%, and the specificity was 75.0%, 100.0%, and 75.0%, respectively. The area under the ROC curve (AUC) for each method was 0.759 6, 0.900 0, and 0.828 8, respectively. Z-test results showed that the AUC of FNAC combined with BRAFV600E mutation detection was improved compared to that of FNAC alone (P=0.008 2). Conclusion This study has found that 78.6% of BRAFV600E mutation-positive cases were classified as categories Ⅴ and Ⅵ in the TBSRTC, indicating that BRAFV600E mutation detection can serve as an important supplementary marker for diagno-sing high-risk PTC nodules. Compared with FNAC alone, the combination of FNAC and BRAFV600E mutation detection improves the preoperative diagnostic accuracy of PTC.

Key words： Fine-needle aspiration cytology; BRAFV600E mutation detection; Papillary thyroid carcinoma; Diagnostics

Cite this article

WANG Lei , JIN Jingjing , YU Na , XIAO Li . Distribution of BRAFV600E mutation in cytological samples of thyroid nodules and its clinical application value[J]. Journal of Diagnostics Concepts & Practice, 2025 , 24(02) : 187 -193 . DOI: 10.16150/j.1671-2870.2025.02.010

References

[1] CHEN D W, LANG B H H, MCLEOD D S A, et al. Thyroid cancer[J]. Lancet,2023,401(10387):1531-1544.
[2] XIE L, WANG S, QIAN Y, et al. Increasing gap between thyroid cancer incidence and mortality in urban Shanghai, China: an analysis spanning 43 years[J]. Endocr Pract,2021,27(11):1100-1107.
[3] CHENG F, XIAO J, SHAO C, et al. Burden of thyroid cancer from 1990 to 2019 and projections of incidence and mortality until 2039 in China: findings from global burden of disease study[J]. Front Endocrinol (Lausanne),2021,12:738213.
[4] GONG Y, JIANG Q, ZHAI M, et al. Thyroid cancer trends in China and its comparative analysis with G20 countries: Projections for 2020-2040[J]. J Glob Health,2024,14: 04131.
[5] DURANTE C, HEGEDUS L, CZARNIECKA A, et al. 2023 European Thyroid Association Clinical Practice Guidelines for thyroid nodule management[J]. Eur Thyroid J, 2023, 12(5).
[6] ALEXANDER E K, CIBAS E S. Diagnosis of thyroid nodules[J]. Lancet Diabetes Endocrinol,2022,10(7):533-539.
[7] BONGIOVANNI M, BELLEVICINE C, TRONCONE G, et al. Approach to cytological indeterminate thyroid nodules[J]. Gland Surg,2019,8():S98-S104.
[8] COZZANI F, BETTINI D, ROSSINI M, et al. Thyroid nodules with indeterminate cytology: association between nodule size, histopathological characteristics and clinical outcome in differentiated thyroid carcinomas - a multicenter retrospective cohort study on 761 patients[J]. Updates Surg,2021,73(5):1923-1930.
[9] WEI X, WANG X, XIONG J, et al. Risk and prognostic factors for BRAF(V600E) mutations in papillary thyroid carcinoma[J]. Biomed Res Int,2022,2022:9959649.
[10] SCHEFFEL R S, DORA J M, MAIA A L. BRAF mutations in thyroid cancer[J]. Curr Opin Oncol,2022,34(1):9-18.
[11] HERNANDEZ B Y, RAHMAN M, LOO L W M, et al. BRAF(V600E), hypothyroidism, and human relaxin in thyroid carcinogenesis[J]. J Cancer Res Clin Oncol,2021,147(1):183-194.
[12] VAN GERWEN M, CERUTTI JM, MENDES TB, et al. TERT and BRAF V600E mutations in thyroid cancer of World Trade Center Responders[J]. Carcinogenesis,2023,44(4):350-355.
[13] CHEN H, SONG A, WANG Y, et al. BRAF(V600E) mutation test on fine-needle aspiration specimens of thyroid nodules: Clinical correlations for 4600 patients[J]. Cancer Med,2022,11(1):40-49.
[14] BALOCH Z W, ASA S L, BARLETTA J A, et al. Overview of the 2022 WHO Classification of Thyroid Neoplasms[J]. Endocr Pathol,2022,33(1):27-63.
[15] HADDAD R I, BISCHOFF L, BALL D, et al. Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology[J]. J Natl Compr Canc Netw,2022,20(8):925-951.
[16] 李玉姝, 单忠艳, 滕卫平. 《甲状腺结节和分化型甲状腺癌诊治指南（第二版）》解读[J]. 中国实用内科杂志, 2023, 43(11): 884-889.
  LI Y S, SHAN Z Y, TENG W P, et al. Interpretation of the guidelines for the diagnosis and treatment of thyroid nodules and differentiated thyroid cancer（second edition）[J]. Chin J Pract Intern Med,2023,43(11):884-889.
[17] 甲状腺细针穿刺细胞病理学诊断专家共识编写组, 中华医学会病理学分会细胞病理学组. 甲状腺细针穿刺细胞病理学诊断专家共识（2023版）[J]. 中华病理学杂志,2023,52(5):441-446.
  Expert Committee of the Consensus on the Cytopathological Diagnosis of Thyroid Fine Needle Aspiration; Section Cyto-logy, Chinese Society of Pathology. Expert consensus on the cytopathological diagnosis of thyroid fine needle aspiration(version 2023)[J]. Chin J Pathol,2023,52(5):441-446.
[18] MAYSON S E, HAUGEN B R. Molecular diagnostic evaluation of thyroid nodules[J]. Endocrinol Metab Clin North Am,2019,48(1):85-97.
[19] WANG Z, YAO Q, BAO L, et al. Clinicopathological features of CCDC6-RET and NCOA4-RET fusions in thyroid cancer: A single-center retrospective cohort study in a Chinese population[J]. Thyroid,2024,34(10):1260-1270.
[20] PRETE A, BORGES DE SOUZA P, CENSI S, et al. Update on fundamental mechanisms of thyroid cancer[J]. Front Endocrinol (Lausanne),2020,11:102.
[21] OKUBO Y, TODA S, KADOYA M, et al. Clinicopathological analysis of thyroid carcinomas with the RET and NTRK fusion genes: characterization for genetic analysis[J]. Virchows Arch,2024,485(3):509-518.
[22] BELLEVICINE C, MIGLIATICO I, SGARIGLIA R, et al. Evaluation of BRAF, RAS, RET/PTC, and PAX8/PPARg alterations in different Bethesda diagnostic categories: A multicentric prospective study on the validity of the 7-gene panel test in 1172 thyroid FNAs deriving from diffe-rent hospitals in South Italy[J]. Cancer Cytopathol,2020, 128(2):107-118.
[23] TANG J, MA J, XI X, et al. Real-life utility of five-gene panel test in preoperative thyroid fine-needle aspiration biopsy: a large cohort of 740 patients study[J]. Endocrine,2023,80(3):552-562.
[24] 赵丽辉, 孙世珺, 易冰, 等. FNAC联合BRAF V600E基因突变检测在甲状腺乳头状癌诊断中的作用及临床意义[J]. 分子诊断与治疗杂志, 2022, 14(04): 669-672, 676.
  ZHAO L H, SUN S J, YI B, et al. The role and clinical significance of FNAC combined with BRAF V600E mutation detection in the diagnosis of papillary thyroid carcinoma[J]. J Mol Diagn Ther,2022,14(4):669-672, 676.
Options
Outlines

/

〈 〉